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SUMMARY. To evaluate T cell immunity in advanced liver
disease, antigen-specific lymphoproliferative (LP) responses
were prospectively studied in the context of the Hepatitis C
Antiviral Long-term Treatment against Cirrhosis trial.
Peripheral blood responses to hepatitis C virus (HCV), tetanus
and Candida protein antigens were measured at baseline,
month 12 (M12), M24, M36 and M48 in 186 patients ran-
domized to either low-dose peginterferon-alfa-2a (PEG-IFN)
only or observation. Liver histologywas evaluated at baseline,
M24 and M48. Patients with cirrhosis (Ishak 5–6) were less
likely to have positive LP responses to HCV at baseline than
patients with fibrosis (15% vs 29%, P = 0.03) and had lower
levels of HCV c100 responses at baseline, M24 and M48
(P = 0.11, P = 0.05, P = 0.02, respectively). For 97 patients
with complete longitudinal data, the frequency of positive LP
responses to HCV, tetanus and Candida antigens declined over
time (P < 0.003), and the slope of this decline was greater
in the PEG-IFN treatment group than the observation group
(P < 0.02). Lower levels of tetanus LP responses were
associatedwith fibrosis progression and clinical outcomes (P=
0.009). Poorer CD4+ T cell proliferative function was asso-
ciated with more advanced liver disease in chronic hepatitis C
and may be further affected by long-term PEG-IFN treatment.
Keywords: cirrhosis, fibrosis, hepatitis C virus, interferon-
alpha, lymphoproliferation, T cell.
INTRODUCTION
Hepatocyte infection by hepatitis C virus (HCV) in vivo is
thought to be noncytopathic. As a consequence, the immune
response to viral infection is believed to play a key role in the
liver damage and ensuing fibrosis that occurs in chronic
infection. However, specific information regarding immune
function during advanced liver disease has been limited, and
longitudinal studies have been rare, in part because of the
protracted natural history of chronic hepatitis C. To evaluate
the relationship between the immune response and liver dis-
ease progression, peripheral blood antigen-specific CD4+
lymphoproliferative (LP) responses were analysed longitudi-
nally over 48 months in a cohort of patients enrolled in the
Hepatitis C Antiviral Long-term Treatment against Cirrhosis
(HALT-C) trial.
The HALT-C trial was a randomized, controlled clinical
trial of patients with chronic hepatitis C and advanced liver
fibrosis (Ishak fibrosis score ‡3) who had not responded to
prior interferon therapy [1]. The main finding of the HALT-C
trial was that long-term low-dose peginterferon-alfa-2a
(PEG-IFN) therapy had no effect in preventing cirrhosis and
its complications in these patients compared to an untreated
control group. During the course of the trial, approximately
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one-third of both treated and untreated patients developed
either increasing hepatic fibrosis on a serial biopsy or a
predefined clinical disease outcome [2]. The HALT-C trial,
therefore, represented an opportunity to prospectively
investigate defects in cellular immune responses in patients
with chronic liver disease, and their possible relationships
with liver disease stage and IFN treatment.
MATERIALS AND METHODS
Patients and study design
The design and results of the HALT-C trial have been de-
scribed [1,2]. Briefly, criteria for enrollment were chronic
HCV infection with detectable HCV RNA, lack of virologic
response to previous interferon-a therapy (with or without
ribavirin) and the presence of bridging fibrosis or cirrhosis on
liver biopsy within 12 months of enrollment. Blood samples
for this ancillary study were prospectively collected as de-
scribed [3]; study protocols were approved by the IRBs of all
participating institutions, and written informed consents
were obtained from all study subjects.
All subjects in this study were treated for 20 weeks with
PEG-IFN 180 lg SQ weekly and ribavirin 1000–1200 mg
p.o. daily (depending on body weight) in two divided doses.
At the week 20 (W20) study visit, serum HCV RNA was
tested in duplicate with the qualitative Roche COBAS
Amplicor v. 2.0 test (Roche Molecular Systems, Branchburg,
NJ, USA). Patients with detectable serum HCV RNA at W20
were randomized at W24 to either low-dose PEG-IFN (90 lg
weekly) or observation for an additional 3.5 years [through
month 48 (M48)]. Patients with undetectable serum HCV
RNA at W20 were excluded from this analysis.
Clinical and laboratory data were collected using stan-
dardized procedures. Serum HCV RNA levels and genotype
were analysed at a central laboratory as previously described
[4]. Liver histology was evaluated and graded by a central
panel of pathologists using the Ishak scoring system at
baseline and at M24 and M48. Predefined clinical outcomes
for the HALT-C trial have been described [1].
Lymphoproliferation assays
Peripheral blood mononuclear cells (PBMC) were isolated and
tested within 24 h of blood draw, after overnight shipment of
blood to the University of Washington. PBMC (105 per well)
were tested in quadruplicate wells with superoxide dismutase
(SOD)-recombinant HCV protein antigens (generously provided
by Kevin Crawford and Michael Houghton, Chiron Corp.,
Emeryville, CA, USA) and control antigens in a 6 day 3H-thy-
midine incorporation assay as previously described [3]. Anti-
gens included yeast-derived SOD (negative control), SOD-c22
(HCV aa 2–120), SOD-c100 (HCV aa 1569–1931), SOD-NS5
(HCV aa 2054–2995) and Escherichia coli-derived SOD-c33c
(HCV 1192–1457). Antigens were aliquoted and kept frozen at
)20 or )80 C as recommended by the manufacturer until
immediately prior to assay, undergoing a total of two freeze/
thaw cycles. Responses to phytohemagglutinin (PHA) (positive
control, 1.6 lg/mL; Remel, Lenexa, KS, USA), Candida albicans
(20 lg/mL; Greer Laboratories, Lenoir, NC, USA) and tetanus
toxoid (12 Lf/mL; Wyeth-Ayerst Laboratories, Marietta, PA,
USA) were also tested. The stimulation index (SI) to individual
HCV antigens was calculated as (mean cpm in the presence of
antigen)/(mean cpm in the presence of appropriate control
antigen). Assayswere considered valid for analysis only if the SI
value for PHA was ‡3. Lymphoproliferation (LP) assays were
scored as positive if the SI value for any HCV antigen or for
tetanus or Candidawas ‡4, as previously described [3].
Statistics
Standard statistical methods (chi-square test, Fisher exact
test, t-test and Wilcoxon rank sum test) were performed with
SAS (Statistical Analysis Software, Cary, NC, USA) version
9.1. Generalized linear mixed models (SAS proc Mixed or
proc GLIMMIX) were used to analyse the changes over time
in the log10 SI or the percentage of subjects who had positive
LP results. All error bars shown in the figures are 95%
confidence intervals for the means from these models; their
width depends on the number of observations for each group
at each time point and does not reflect outliers within a
particular group. To evaluate the association of clinical and
histological outcomes with log10 SI, we included a time-
varying covariate with two categories: whether or not the
patient met the definition of an outcome at or before the date
of the visit at which the LP response was measured. All
analyses were two-tailed with a = 0.05.
RESULTS
The data in Table 1 illustrate the baseline clinical, demo-
graphic and laboratory parameters of the 186 HCV-infected
subjects included in this analysis. Proliferative responses to
C. albicans, tetanus toxoid and HCV protein antigens were
prospectively measured as described in Materials and
Methods. Over all visits, positive LP responses were found
most commonly to HCV antigens c100 (HCV NS4) >c22
(HCV core) >NS5 or c33c (HCV NS3); this hierarchy of
responsiveness to specific HCV antigens did not vary over
time (data not shown). Among all patients tested at baseline,
44/186 (24%) patients had LP responses to any HCV anti-
gen, 150/186 (81%) had LP responses to tetanus, and 162/
186 (87%) had LP responses to Candida.
The percentage of positive lymphoproliferative responses
declined over time during the Hepatitis C Antiviral Long-
term Treatment against Cirrhosis trials
The percentage of subjects with positive LP responses to HCV
antigens declined significantly over time according to study
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visit (P < 0.0001, Fig. 1), as did responses to the recall
antigens, Candida and tetanus (P < 0.0001). The Candida
protein antigen was obtained periodically from the manu-
facturer on an as needed basis (range 3–10 months per lot,
median every 5 months). The HCV antigens and tetanus
toxoid were obtained at the beginning of the study and used
for the duration of follow-up. Patients were enrolled into the
HALT-C trial over a period of 2.5 years, and tests were
performed over a period of 7 years. To determine the impact
of antigen storage on our results, we investigated whether
the frequency of positive LP responses to tetanus and Candida
antigens varied during the approximately 2.5 year window
for each study visit. No significant changes in the percentage
of LP-positive responses over the 2.5 years were found for
either tetanus or Candida antigens (data not shown). Time-
dependent changes in the LP results were found when the
data were analysed over serial visits or according to the year
in which the data were generated; however, the decline over
serial visits remained significant after adjusting for the year
in which the assay was performed (P = 0.009 for both
tetanus and Candida). The same statistical analysis could not
be performed for HCV antigen responses because of the
substantially lower frequency of positive responses.
Over time, lymphoproliferative responses decreased
in patients randomized to low-dose pegylated interferon-
alfa treatment compared to observation
To investigate the impact of long-term PEG-IFN therapy on
antigen-specific LP responses, we analysed data from 97
patients (44 control and 53 treatment) with available LP
data at all of the following study visits: baseline, M12, M24,
M36 and M48. The frequency of positive LP responses
declined over time in both treated and untreated patients
Table 1 Study subjects and baseline data
Variable
Control % or
mean (SD) n = 93
Treatment % or
mean (SD) n = 93 P-value*
Age (years) 50.9 (8.8) 51.5 (7.0) 0.63
Gender (Female) 32% 31% 0.88
Race (Caucasian) 75% 75% 1.00
HCV genotype 1 96% 94% 0.75
HCV RNA (Log10 IU/ml) 6.54 (0.46) 6.48 (0.50) 0.38
ALT (U/L) 96.6 (70.8) 92.7 (50.5) 0.67
Albumin (g/dL) 3.96 (0.39) 3.95 (0.42) 0.80
INR 1.05 (0.11) 1.05 (0.10) 0.95
Bilirubin (mg/dL) 0.84 (0.38) 0.90 (0.48) 0.30
Platelets (·1000/mm3) 164.0 (65.5) 155.5 (61.4) 0.36
Cirrhosis 38% 35% 0.76
HAI 6.77 (1.97) 7.20 (2.43) 0.19
WBC (·1000/mm3) 5.99 (1.74) 5.68 (1.87) 0.24
Neutrophils (·1000/mm3) 3.27 (1.28) 3.05 (1.30) 0.24
WBC-neutrophils (ANC) counts 2.72 (0.86) 2.63 (0.90) 0.50
*T-test or Fishers exact test was used. ALT, alanine aminotransferase; HCV, hepatitis C virus; INR, International normalized
ratio; HAI, hepatic activity index.
Fig. 1 Decreased frequency of positive lymphoproliferative
responses during the Hepatitis C Antiviral Long-term
Treatment against Cirrhosis trial according to study visit.
Proliferative responses by freshly isolated peripheral blood
mononuclear cells to hepatitis C virus (HCV) protein
antigens, tetanus toxoid and Candida albicans antigens were
measured using a 3H-thymidine assay. The threshold for
positivity was defined as a stimulation index (SI) of ‡4 for all
antigens, and an HCV response was considered to be posi-
tive if an SI of ‡4 was achieved for one or more HCV
antigens. All useable assay results available at each study
visit were included, and the number of individual assay
results at each study visit is shown below the x-axis. 95%
confidence intervals are shown.
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(P < 0.003); however, fewer PEG-IFN-treated patients were
found to have positive LP responses to HCV, tetanus toxoid
and C. albicans protein antigens over all study visits except
baseline (Fig. 2a, P = 0.002; b, P = 0.0002; and c,
P = 0.02). Note that patients who had a positive LP result to
any of the four HCV antigens tested were considered among
those with positive HCV responses (Fig. 2a). Statistically
significant differences between treated and untreated groups
were also obtained when LP responses to HCV c100 (only),
tetanus and Candida antigens were analysed as the mean of
the log10 SI of all samples at each study visit (including those
with SI <4.0) (Fig. 2d, P = 0.009; e, P = 0.0008; and f,
P = 0.09).
Clinical associations with lymphoproliferative assays at
baseline and during the randomized phase of the Hepatitis
C Antiviral Long-term Treatment against Cirrhosis trial
At baseline, a smaller percentage of patients with cirrhosis
had positive HCV-specific responses (15%) compared to those
with fibrosis (29%, P = 0.03). At M24 and M48, the other







Fig. 2 Lymphoproliferative responses decrease over time according to treatment status. Proliferative responses by peripheral
blood mononuclear cells (PBMC) to hepatitis C virus (HCV) protein antigens (a), tetanus toxoid (b) and Candida albicans
(c) antigens were measured as described in Fig. 1. Mean stimulation indices of all useable assay results at each study visit
(including assays with SI ‡ and <4.0) are indicated (d, e and f). Log10 SI were derived by subtracting the log10 mean cpm of
unstimulated wells by the log10 mean cpm of stimulated wells. Error bars indicate 95% confidence intervals. Results were
categorized according to whether PBMCs were obtained from patients randomized to long-term peginterferon-alfa-2a (PEG-
IFN) treatment (black symbols/solid lines) or to observation (control, open symbols/dashed lines). This analysis was restricted
to patients with complete data at all study visits (44 control patients and 53 treatment patients). Fewer PEG-IFN-treated
patients had positive or lower level LP responses to HCV protein antigens (a, P = 0.002; d, HCV c100, P = 0.009), tetanus
toxoid (b, P = 0.0002; e, P = 0.0008) and C. albicans (c, P = 0.02; f, P = 0.09).
 2011 Blackwell Publishing Ltd
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frequency of HCV LP-positive responses was not statistically
significantly different between patients with fibrosis and
cirrhosis as measured at those study visits (Fig. 3a). How-
ever, an analysis of the mean log10 SI to HCV c100 antigen
demonstrated statistically significant differences between the
fibrosis and cirrhosis groups at M24 (P = 0.0497) and M48
(P = 0.02), respectively (Fig. 3b). A similar analysis of the
mean log10 SI to HCV c22 (core), the next most frequently
detected HCV-specific response, did not reveal any relation-
ship with cirrhosis (data not shown). No differences in the
proportion of fibrotic and cirrhotic patients with LP-positive
responses to either tetanus or Candida were found at any
study visit.
To further evaluate an association between lack of
lymphoproliferation and advanced liver disease, we inves-
tigated the relationship between LP responses and the
occurrence of previously defined clinical outcomes
(including hepatic decompensation) or a two point increase
in the Ishak fibrosis score in serial biopsies. No statistically
significant associations were found in these analyses using
positivity thresholds for the LP data (SI ‡4, data not
shown). We also analysed the data using the mean log10
SI at each study visit and a time-varying covariate
according to whether patients experienced the combined
disease outcomes or not (Fig. 4). These results indicate
that patients who experienced fibrosis progression or other
disease outcomes had lower mean LP responses to tetanus
over time (P = 0.009) compared to those without out-
comes (Fig. 4b,e). No statistically significant differences in
HCV or Candida LP responses were detected (Fig. 4a,c,d
and f).
We then evaluated the data set for relationships between
circulating platelet counts and LP results, because a
decreased platelet count is a commonly observed manifes-
tation of severe liver disease/portal hypertension and has
been used in clinical models to predict the likelihood of cir-
rhosis [5,6]. Only patients who had positive LP responses at
baseline were included in this analysis. We then compared
platelet values at M12, M24, M36 and M48 according to LP
status (positive or negative) at those study visits (Table S1).
Mean platelet counts were consistently lower in patients
who lost LP responses to Candida and tetanus antigens
compared to those who did not, although the results were
only statistically significant at M36 for Candida and M24 for
tetanus in the untreated control group. Similar results were
found for the treated groups who lost or maintained LP
responses, but this could have been influenced by the
thrombocytopenic effects of PEG-IFN. HCV-specific responses
were not analysed because of the much smaller sample size
of those with positive responses.
DISCUSSION
These studies demonstrate that HCV-specific as well as recall
antigen-specific LP responses declined over time in a large
group of prospectively monitored patients with advanced
chronic hepatitis C who were IFN-nonresponders, regardless
of whether a positivity threshold was applied or whether all
proliferative responses were considered using log10-trans-
formed SI values. Treatment with PEG-IFN appeared to
substantially augment this anti-proliferative and potentially
immunosuppressed state. Importantly, we describe for the
first time a relationship between measures of advanced liver
disease and LP responses. Lack of and lower levels of HCV-
specific LP responses were associated with the presence of
cirrhosis, and lower levels of lymphoproliferation stimulated
by tetanus toxoid were associated with fibrosis progression
and clinical outcomes. Loss of tetanus and Candida LP
responses over multiple years of follow-up (as indicators of a
general decline in CD4+ T cell memory responses) was also
(a)
(b)
Fig. 3 Lack or lower levels of lymphoproliferation to hepa-
titis C virus (HCV) antigens are associated with cirrhosis.
Patients were categorized according to whether they had
fibrosis (Ishak 3–4) or cirrhosis (Ishak 5–6), measured at
each biopsy study visit. The percentage of patients with
positive HCV-specific lymphoproliferative responses (SI
‡4.0) to any HCV protein antigen (a) or corresponding
mean log10 SI to HCV c100 antigen (including assays with
SI ‡ and <4.0) at each study visit is shown (b). Both treated
and untreated patients are included at months 24 and 48.
Numbers of patients in each group are indicated. P-values
are from separate analyses at each study visit. All error bars
indicate 95% confidence intervals.
 2011 Blackwell Publishing Ltd
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associated with lower platelet counts, a surrogate measure of
advanced liver disease.
Despite the sizable cohort enrolled in this study (n = 186
at baseline), many of the analyses were hindered by
insufficient sample size. Specifically, the analyses were
limited by the number of patients with positive LP
responses to various antigens at each study visit, the
number of patients who developed clinical or fibrosis out-
comes and had serial LP results available and the need to
analyse treated and untreated patients separately to ac-
count for confounding effects of PEG-IFN. For example,
serial HCV c100-specific responses could be analysed over
time (Figs 3b and 4), but trends in LP responses to the
other HCV antigens could not be analysed because of the
low frequency of positive responses. Moreover, because this
study was not specifically designed to address the loss of LP
responses to tetanus and Candida antigens over time, we
did not perform longitudinal LP assays on a comparison
group of HCV-uninfected subjects. Inclusion criteria for the
HALT-C trial, such as prior nonresponse to IFN treatment,
could also limit the generalizability of the findings. Despite
these limitations, we report novel observations regarding
serial measurements of a critical function of CD4+ T cells
in a sizable population of HCV-infected patients with








Fig. 4 Decreased levels of lymphoproliferative (LP) responses to tetanus are associated with clinical and fibrosis outcomes.
Mean log10 SI (including assays with SI ‡ and <4.0) and 95% confidence intervals of proliferative responses to hepatitis C
virus (HCV) c100 (a, d), tetanus toxoid (b, e) and Candida albicans (c, f) antigens are shown. For clarity, results from patients
randomized to observation (a–c) were separated from those randomized to long-term pegylated interferon-alfa treatment (d–f).
Results from patients with outcomes (open symbols/dotted lines) and those with no outcomes (closed symbols/solid lines) are
indicated. This analysis included 93, 79, 67, 65 and 56 control patients and 93, 74, 79, 73 and 70 treated patients at baseline
M12, M24, M36 and M48, respectively. The confidence intervals are wide at month 12 because there were few patients in the
outcome group at that time. Patients with clinical and fibrosis outcomes had lower LP responses to tetanus toxoid (b and e,
P = 0.009), but not HCV c100 (a and d, P = 0.46) or C. albicans (c and f, P = 0.35).
 2011 Blackwell Publishing Ltd
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Clinical observations and studies of ex vivo T cell function
have indicated that patients with chronic hepatitis C are
not globally immunosuppressed [7,8]. However, attenua-
tion of HCV-specific immune responses has clearly been
demonstrated [9,10]. Past studies of antigen-specific lym-
phoproliferation utilized peripheral blood samples from
treatment-naive chronic hepatitis C patients, of whom only
a small minority had advanced hepatic fibrosis [11–13]. By
contrast, the patients in this study were a group of IFN-
experienced patients who had previously demonstrated a
lack of virologic response to treatment, with an interval of
0.8–12 years (median 1.8 years) between last IFN and
baseline testing. These patients were also required to have
a minimum of bridging fibrosis (Ishak fibrosis score ‡3) to
enter the study. Despite this past history of treatment and
virologic nonresponse, approximately 25% of patients
exhibited an HCV-specific LP response at baseline and 94%
of patients had a recall memory response to either tetanus
or Candida and 74% to both. By these measures, the fre-
quency of LP responsiveness at baseline was generally
consistent with past reports indicating a diminished HCV-
specific response but otherwise intact immunity. At this
baseline study visit, when our sample size was largest, a
lack of HCV-specific LP responses was significantly associ-
ated with the presence of cirrhosis on liver biopsy
(P = 0.03, Fig. 3). Although more patients with cirrhosis
also lacked HCV-specific LP responses at later study visits,
these differences did not reach statistical significance. This
may have been related to the low number of positive HCV-
specific LP responses at these later study visits (4/49 vs 15/
81 at M24 and 1/52 vs 4/58 at M48 in cirrhotic vs fibrotic
patients, respectively). However, an analysis of HCV c100-
specific lymphoproliferation using SI values rather than
positivity (Fig. 3b) further reinforced the association
between lack of proliferation and cirrhosis.
During the 42-month follow-up period, approximately
one-third of the 186 patients evaluated developed liver
fibrosis progression or clinical outcomes/hepatic decompen-
sation (combined disease outcomes). No association was
found between LP results and combined disease outcomes
using a defined threshold for positive LP results. However, an
association was identified between lower tetanus SI (a mea-
sure of memory T cell responses) and combined disease
outcomes (Fig. 4). As greater power is usually obtained with
continuous rather than categorical variables, the absence of
an association with dichotomous (positive/negative) LP
results may have been related to sample size limitations.
Other indirect measures of liver disease progression such as
low platelet counts were also found to be associated with the
loss of lymphoproliferation to recall antigens. Together,
these results suggest that lack or loss over time of LP func-
tion may be associated with the presence of cirrhosis.
Our data also provide a functional correlate for a recent
report describing the association of abnormally low CD4+ T
cell counts (but not CD4+ T cell percentages) with spleno-
megaly or thrombocytopenia among a heterogeneous group
of cirrhotic patients (all HIV seronegative) [14]. CD4+ T cell
frequencies were not measured in our study, but an overall
loss of CD4+ memory T cell numbers was unlikely to affect
our results, because the input number of PBMC in each test
well was consistent among all assays and the authors
reported no association with CD4+ T cell percentages.
Consistent with these peripheral blood data of McGovern
et al., Bonacini et al. [15] described a significant decrease in
the frequency of portal/periportal CD4+ T cells and lobular
CD4+ and CD8+ T cells in patients with cirrhosis compared
to those with less advanced stages of fibrosis. Data on T cell
function in HCV-induced liver cirrhosis are sparse; Anthony
et al. [16] reported fewer IFN-c ELISpot responses to HCV
core antigen in 21 cirrhotic patients compared to 17 without
cirrhosis, while NS3-specific responses were intact. Although
the antigen-specific associations and lymphocyte function
measured differed from our study, they too found decreased
immune responsiveness among patients with cirrhosis.
Thus, our data provide additional functional evidence to
support the notion that T cell immunity is impaired or dys-
regulated in advanced hepatic fibrosis.
Ageing is associated with a decline in in vitro T cell pro-
liferative function as well as in vivo T cell immunity [17]. The
mean age of the patients tested in this study was approxi-
mately 50 years at baseline (range 19–75, Table 1). Thus, it
is possible that a natural decline in immune function could
have contributed to the results found here, because the fre-
quency of positive LP responses decreased with study visit,
which also corresponded to ageing of the cohort. Subjects
lacking baseline tetanus LP responses were older (mean
55 years) than patients with response (mean 50 years,
P = 0.0006), but no significant differences in age were
found according to LP responses to HCV (P = 0.79) or
Candida (P = 0.88).
Another important possibility to consider is that ageing
and/or cirrhosis could be associated with a decline in anti-
gen-presenting function, which was manifest in our study as
a loss of T cell proliferative function. Such a scenario has
been described for chronic alcohol exposure, where ethanol
has been shown to adversely affect antigen-presenting
function as well as T cell proliferative function [18]. How-
ever, future studies will be necessary to determine whether
defects in T cell function alone or both T cell and antigen
presentation functions are present in HCV-associated
advanced liver disease.
Treatment with PEG-IFN monotherapy in vivo led to a
further reduction in the number of patients with positive LP
results to any antigen. Although this finding may be
explained by the anti-proliferative effects of IFN [19,20],
other reports indicate that the effects of type I IFNs on T cells
are more complex. Several groups have described inhibitory
effects of IFN on proliferative responses of naive but not
activated T cells [21,22]. It has also been reported that IFN
treatment can affect the apoptotic death and/or survival of
 2011 Blackwell Publishing Ltd
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activated lymphocytes [21,23] and that T cell responses can
be influenced by prior exposure to IFN [22]. Multiple studies
in treatment-naive cohorts have reported that HCV-specific
LP responses increase in frequency during and after IFN
treatment in those who clear HCV [11–13]. Such results are
consistent with a recent report that addition of IFN in vivo or
in vitro to memory T cells from HCV-infected patients led to
an enhancement of proliferative responses to PPD antigen
[24]. However, in the same study, proliferative responses to
tetanus toxoid or influenza A hemagglutinin were dimin-
ished in the presence of IFN in some of the patients tested.
Recently, Burton et al. [25] reported a reduction in the fre-
quency of HCV-specific IFN-c responses during IFN plus
ribavirin therapy compared to baseline, although the same
was not true for CMV control responses in the cohort. Other
groups have also reported that IFN plus ribavirin therapy is
not always associated with increased LP responses to HCV
antigens [26,27]. Thus, the effects of type I IFN on T cells
could differ according to activation status, memory pheno-
type, antigen specificity, HCV RNA levels, lymphocyte
function tested and other factors. Further investigation will
be necessary to elucidate the critical factors and mechanisms
underlying the observed effects of in vivo IFN treatment on
antigen-specific CD4+ T cell function.
Bacterial infection, including spontaneous bacterial peri-
tonitis, is a frequent complication of advanced fibrosis and
cirrhosis. Many factors are thought to contribute to the
increased susceptibility of these patients to infection,
including impaired reticuloendothelial cell and polymor-
phonuclear cell function, portosystemic shunting, altera-
tions in enteric flora, malnutrition, compromised natural
barriers and invasive diagnostic and therapeutic procedures
[28,29]. Our finding that in vivo PEG-IFN treatment
induced a generalized impairment of CD4+ T cell prolifer-
ative function complements the recent observation that
overall CD4+ T cell counts (but not percentages) declined
during PEG-IFN therapy [30] and suggests a potential role
for CD4+ T cell immunity in influencing infection risk in
this population. Our results could also help to explain the
observation that the incidence of bacterial infections was
higher among PEG-IFN-treated patients with cirrhosis
awaiting liver transplantation compared to untreated con-
trols [31]. Whether impairment of T cell immunity is
pathogenetically involved or a bystander effect of the pro-
cess of liver disease progression will need to be addressed by
future studies. However, the depressed T cell immunity
described here could contribute to the increased suscepti-
bility of chronic hepatitis C IFN-nonresponder patients with
advanced liver disease to infection as well as to the devel-
opment of cancer.
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